Publikasi Scopus FKUI 2021 per tanggal 30 Juni 2021 (428 artikel)

Nurhayati F., Anggriani Y., Syahruddin E., Ramadaniati H.U., Kusumaeni T.
57222957631;57144482600;6507688750;56380618600;57196083946;
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
2021
Journal of Applied Pharmaceutical Science
11
4
88
95
Pharmacy Department, Persahabatan Government Hospital, Jakarta, Indonesia; Faculty of Pharmacy, University of Pancasila, Jakarta Selatan, Indonesia; Division of Thoracic Oncology Department of Pulmonology Respiratory Medicine Faculty of Medicine, Universitas Indonesia Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia
Nurhayati, F., Pharmacy Department, Persahabatan Government Hospital, Jakarta, Indonesia; Anggriani, Y., Faculty of Pharmacy, University of Pancasila, Jakarta Selatan, Indonesia; Syahruddin, E., Division of Thoracic Oncology Department of Pulmonology Respiratory Medicine Faculty of Medicine, Universitas Indonesia Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia; Ramadaniati, H.U., Faculty of Pharmacy, University of Pancasila, Jakarta Selatan, Indonesia; Kusumaeni, T., Pharmacy Department, Persahabatan Government Hospital, Jakarta, Indonesia
Tyrosine kinase inhibitors (TKIs; e.g., erlotinib, gefitinib, and afatinib) are the first-line therapy for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) (+) common mutation. The study’s objective was to analyze the cost-effectiveness of erlotinib, gefitinib, and afatinib in NSCLC patients. The subjects of the study were NSCLC patients with EGFR (+) mutation receiving either erlotinib, gefitinib, or afatinib from January 2017 to December 2019. The exclusion criteria were patients receiving the respective therapy for less than 2 months and patients unable to complete the treatment until after December 2019. The parameter of treatment effectiveness was progression-free survival (PFS), which was measured as the time from initiation of the therapy until disease progression occurred or a patient became deceased. Direct medical costs, from the hospital perspective, were calculated during the treatment. A nonparametric Kruskal-Wallis test was conducted to compare the median PFS and direct medical cost between the three treatment groups. The median PFS of patients receiving erlotinib, gefitinib, and afatinib was 8 months, 12 months, and 5 months, respectively. There were significant differences in the monthly direct medical costs between the study groups: erlotinib (IDR 13,545,116), gefitinib (IDR 14,727,887), and afatinib (IDR 12,146,834). The cost-effectiveness ratio of the study groups was as follows: erlotinib IDR 1,693,139.50/months; gefitinib IDR 1,227,323.92/months; and afatinib IDR 2,429,366.80/months. Gefitinib was the most cost-effective TKI, followed by erlotinib and afatinib. © 2021. Fitri Nurhayati et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). All rights reserved.
afatinib; Cost-effectiveness; erlotinib; gefitinib; non-smallcell lung cancer.
Open Science Publishers LLP Inc.
22313354
Article
Q2
252
16109